retatrutide ly3437943 phase 2 trial obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide produces up to 30.3%

Modeling based on current utilization suggests these price reductions could generate $932.7 million in savings, sufficient to offset treatment costs for approximately 550 000 additional beneficiaries eligible for expanded #obesity coverage

Printable Journals : Physical trackers for injections, weight, and symptoms, ideal for those who prefer pen and paper

Once enrolled, your visits are efficient: check-ins typically run 20 to 30 minutes, covering your injection, progress review, side-effect management, and any dosage adjustments

More than half of GLP-1 users (52%) say they spend less money eating out than they used to, and 42% say they have reduced or eliminated the amount they used to spend on other weight loss programs or methods

How quickly can facial volume loss appear during GLP-1 weight loss treatment

Were going to be rolling these out over time